Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Chikungunya is a disease that is caused by the chikungunya virus which is transmitted to humans by infected mosquitoes. Its name is derived from a word in the Makonde language that means contorted or ...